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programs, participation rates remain low in countries that have implemented such
a screening program. Besides the diagnostic accuracy and the risks of the screening
technique that affect the health of the participants, additional factors, such as the
burden of the test, may impact the individuals’ decisions to participate. The aim of
this study it to explore the impact of preferences for the attributes of screening
tests on intention to attend a colorectal cancer screening program. METHODS: We
used a web-based questionnaire to elicit the preferences of Dutch men and woman
aged 55 to 75 years for alternative colon screening techniques, and to measure their
intention to attend the screening. The Analytic Hierarchy Process (AHP), a tech-
nique for multi-criteria analysis, was used to estimate the colorectal cancer screen-
ing preferences for iFOBT, Colonoscopy, Sigmoidoscopy and Virtual Colonoscopy.
RESULTS:We included 167 respondents that were consistent in their judgments on
the relevance of the criteria and the preferences for the screening techniques. The
results indicate that the most preferred screening methods with the highest inten-
tion to attend were Virtual Colonoscopy and iFOBT. Sensitivity and safety of the
screening methods were the strongest determinants of the overall preference for
the screening techniques. However, safety and inconvenience were most strongly
related to intention to attend. CONCLUSIONS: Even though for the long term the
respondents may recognize the high importance of diagnostic effectiveness, their
short term decision to attend the screening tests appears to be less driven by this
consideration. Our analysis suggests that inconvenience and safety will be the
strongest technique-related determinants of the respondents’ decision to partici-
pate in the new screening program in the Netherlands.
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OBJECTIVES: Although transcatheter aortic valve implantation (TAVI) is effective
and less invasive than surgery, its superiority in terms of costs and quality of life is
controversial and has not been well demonstrated in “real life” patients. The pri-
mary objective of the TEVAS study is to evaluate cost-utility of TAVI vs conven-
tional surgery and conservative treatment. In this preliminary analysis we present
clinical results, resource use, and changes in quality of life during the first month
after TAVI in a real life setting. METHODS: Candidate patients were recruited pro-
spectively at the time of indication in 7 Spanish hospitals. A centralized follow-up
was performed by phone one month after intervention. We measured utility with
EQ5D and specific quality of life with the Heart-QoL questionnaire. RESULTS: A
total of 109 patients were recruited in the TAVI group and follow-up at one month
was available for 66. Mean age: 80.8 (SD:6.6), mean logistic EuroSCORE: 14 (SD:12.6)
(median:10.32, Q1-Q3:6.2-18.6). Four patients (6%) had severe complications after
TAVI (AMI, stroke or need for a second valve) and 8 (12.1%) died in the first 30 days
after TAVI. Among survivors, EQ5D score improved significantly from baseline
(0.61, SD:0.33 to 0.72, SD:0.31; p-value:0.01) and so did the Heart-QoL overall score
(1.44, SD:0.77 to 2.07, SD:0.58; p-value0.001). During the first month of follow-up
there were a mean of 0.89 visits per patient to the family physician, 0.40 to a
specialist and 0.44 to the nurse. Six patients (10.3%) had at least one readmission
(7% for cardiovascular causes; mean hospital length of stay: 6.8 days per patient).
CONCLUSIONS: Although quality of life improves substantially in the first month
after TAVI, in preliminary analysis resource use still remains high.
PMD74
THE RELATIONSHIP BETWEEN TREATMENT SATISFACTION AND HEALTH
STATUS AMONG THOSE WITH TYPE 1 DIABETES
Pignot M1, Eichmann F2, Dibonaventura MD3
1Kantar Health, München, Bavaria, Germany, 2Kantar Health GmbH, München, Germany,
3Kantar Health, New York, NY, USA
OBJECTIVES: Patients with type 1 diabetes (T1D) can achieve glycemic control ei-
ther through multiple daily injections or by using insulin pump therapy (IPT). How-
ever, real-world data on these treatments is lacking. The objective of this study was
to compare the levels of treatment satisfaction between patients using IPT versus
those not and to examine the relationship between treatment satisfaction and
health status. METHODS: Unique respondents from the 2009, 2010, and 2011 U.S.
National Health and Wellness Surveys were pooled together for analysis. All re-
spondents who reported a diagnosis of T1D were included. Those using IPT were
compared with those not using IPT. The relationship between satisfaction and
health status was also examined using multiple linear regression models (control-
ling for sociodemographics and health history variables) among all T1D patients
using insulin. Health status was assessed using the SF-12v2 instrument. RESULTS:
Of the 1441 patients who reported being diagnosed with T1D and were currently
using insulin, 379 reported using IPT (26.3%). Patients using IPT reported signifi-
cantly higher levels of satisfaction with their treatment (6.0 vs. 5.8, p.05). Among
all patients with T1D and using insulin, satisfaction was significantly associated
with greater health status across all summary and domain scores of the SF-12
including: mental component summary (b1.64), physical component summary
(b0.84), bodily pain (b1.34), vitality (b3.74), physical functioning (b3.11), phys-
ical role limitations (b3.45), emotional role limitations (b2.87), general health
(b3.16), mental health (b3.34), social functioning (b3.79), and health state util-
ities (b0.02) (all p.05). Satisfaction was also significantly associated with less
impairment in daily activities (b-2.44). CONCLUSIONS: Patients using IPT re-
ported significantly greater satisfaction and satisfaction was associated with
greater health status and reduced activity impairment. Further research is neces-
sary to uncover the mechanisms of these relationships but these findings suggest
that the patient’s perspective of their treatment is strongly associated with health
outcomes.
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OBJECTIVES: Fifty-one percent of people do not participate in non-invasive colo-
rectal cancer screening. One of the reasons may be the prospect of a future invasive
follow-up test (colonoscopy). We investigate how follow-up test information af-
fects peoples’ participation decision and screening test preferences and expect a
negative effect on participation when colonoscopy is specified as follow-up test.
METHODS: Attributes and levels in the DCE are based on a literature review and
analysis of CRC related mortality-risk (data Erasmus MC). We created a labeled and
blocked efficient design with zero priors and restrictions in Ngene. The labels rep-
resent three different screening tests (a stool-test, blood-test, combi-test) and a
non-participation option. Two follow-up test specification versions and 3 blocks
resulted in six different web-based survey versions of 12 choice sets each. The
colonoscopy specification version presents respondents an additional follow-up
test attribute with colonoscopy as a fixed attribute level and detailed colonoscopy
information. The non-colonoscopy specification version doesn’t present respon-
dents a follow-up test and follow-up test information. Respondents were randomly
assigned to one of the survey versions. Data of 631 Dutch respondents, aged 55-75
years, is used in the analysis. RESULTS: MNL model results show a positive signif-
icant effect on screening test choice for the attributes sensitivity, risk reduction,
and level of evidence, and a negative effect of 1-specificity. The significant negative
interaction effects of the alternative specific constants with follow-up test specifi-
cation indicate that uptake would be lower in case a colonoscopy is specified (83.8%
versus 88.6%). Furthermore, the difference between the (more preferred) combi-
test relative to the other tests diminishes for the colonoscopy specification. A
nested logit model doesn’t indicate scale differences. CONCLUSIONS: People’s
screening test preferences are affected by invasive follow-up test (colonoscopy)
information presented in the survey. This result is interesting for policy makers
that aim to optimize uptake.
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OBJECTIVES: Glycemic control for patients with type 1 diabetes (T1D) can be
achieved either through multiple daily injections or through insulin pump therapy
(IPT). Currently, there is a lack of real-world data on the differences in these treat-
ment options, particularly as they relate to patient-reported outcomes. The objec-
tive of this study was to investigate the effect of IPT on health status among pa-
tients with T1D. METHODS: Data from unique respondents from the 2009, 2010,
and 2011 U.S. National Health and Wellness Surveys were used. Among respon-
dents who reported a diagnosis of T1D and reported using insulin, those who
reported using IPT were compared with those who were not using IPT on summary
and domain scores of the SF-12v2 using general linear models controlling for so-
ciodemographic and health history differences. RESULTS: A total of 1,441 patients
reported being diagnosed with T1D and were currently using insulin. Of these
patients, 379 reported using an insulin pump (26.3%). Patients using an insulin
pump had been diagnosed for longer (26.8 vs. 21.2 years) and were significantly
more likely to be female (53.8% vs. 43.3%), be non-Hispanic white (87.6% vs. 68.6%),
have an annual household income of $75K or more (27.7% vs. 18.9%), and possess
health insurance (95.05 vs. 84.8%) (all p.05). Adjusting for these differences, pa-
tients using an insulin pump reported significantly better physical health status
(44.76 vs. 42.51) and health utilities (0.71 vs. 0.68). Similar significant differences
were observed on domain scores of the SF-12. CONCLUSIONS: Although T1D pa-
tients with greater health care access were more likely to use IPT, even after ad-
justing for these differences, a significant effect of IPT was observed on health
status. These results suggest that IPT may be associated with greater real-world
effectiveness, though additional research is necessary.
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OBJECTIVES: The acute back pain arising in relation to vertebral compression frac-
tures (VCFs) has traditionally been viewed as the most important driver for the
health-related quality of life (QoL) decrement associated with the fracture. The
objective was to quantify the impact of different health dimensions on overall
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quality of life using the EQ-5D collected in the SWISSspine registry.METHODS: The
analysis was based on the SWISSspine registry, covering BKP treatment of 1027
fractured vertebrae in 765 patients with osteoporosis, trauma and cancer, from
2005–2011 in Switzerland. In the registry, data is collected before operation and at
follow-ups at 3–6 months, 1 year and annually thereafter. The health-dimensional
contribution to the overall quality of life improvements was analysed by isolating
the impact of each dimension on quality of life based on the EQ-5D. It was assumed
that the change in QoL over one year was solely due to treatment received.
RESULTS: Mean age was 70.4 years and 70.1% of the patients were women. The
mean accumulated QoL improvement compared to pre-surgery over one year was
0.40, 0.46 and 0.38 for osteoporotic, trauma and cancer patients, respectively.
Changes in pain, as measured by EQ-5D, explained 45% of the QoL change for
osteoporotic patients, 40% for patients with cancer and 35% for patients who suf-
fered trauma. Mobility and self-care were the second and third most important
dimensions respectively, varying between 19–29% for all indications. Improve-
ment in usual activities contributed 9–14% to improvement in quality of life and
anxiety 2–7%. CONCLUSIONS: Changes in the pain dimension of health are the
most important driver for overall quality of life in patients treated with BKP. How-
ever, ignoring the impact of mobility and self-care would lead to an underestima-
tion of the actual improvement in overall quality of life.
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OBJECTIVES: To evaluate the metabolic effect of adding continuous glucose mon-
itoring (CGM) to insulin pump therapy and the impact on Health Related Quality of
Life (HRQOL), Treatment Satisfaction (TS).METHODS: Eighty-one adults & seventy-
two children with Type 1 diabetes participated in a multicenter, randomized, con-
trolled, cross-over study. Following a one month run-in period, subjects were ran-
domized to CGM Sensor-ON or Sensor-OFF arms for six months, following a four
month wash-out period subjects crossed over to the other treatment arm for six
additional months. Diabetes Treatment Satisfaction Questionnaire (status version;
DTSQs) in adults and Pediatric Quality of Life Inventory (PedsQL) in children were
collected at baseline and end of each treatment period. Analyses were controlled
for baseline values, and there was no sequence effect observed in either age group.
RESULTS: Sensor use significantly improved glycemic control resulting in an
HbA1c reduction of -0.43% in the intention to treat population (ITT). Adult TS im-
proved significantly (p0.012) compared to baseline, favoring Sensor-ON in ITT.
There was no significant difference in the perceived frequency of hypo- or hyper-
glycemia with CGM. Sensor use was positively associated with TS (p0.027) in the
per-protocol group. There was no significant difference in children’s perceived
overall HRQOL between Sensor-ON and Sensor-OFF. Individual items of the PedsQL
and DTSQs were analyzed separately. CONCLUSIONS: Adding CGM to pump ther-
apy significantly improves metabolic control. CGM use significantly improves
treatment satisfaction in adults, and had no impact on the overall HRQOL in chil-
dren. Increased usage of the sensor was associated with an increase of the TS score
in adults.
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OBJECTIVES: To describe the use and cost of blood glucose monitoring test strips
(BGMTS) in the first year of treatment with antidiabetes drugs. METHODS: We
conducted a population-based cohort study using the Quebec (Canada) Health In-
surance Board data. The cohort was made of Quebec inhabitants aged  18 years,
who initiated an antidiabetes (AD) treatment made of a monotherapy of sulfonyl-
urea, metformin, or insulin between January 1, 2000 and December 31, 2007 and for
whom we had at least one year of follow-up in the database. New users were those
with no insulin or oral AD claim in the 12 months prior to the first insulin or oral AD
dispensing date (treatment initiation). Use and cost of BGMTS during the 365 days
following treatment initition were described according to the class of drug initially
taken. RESULTS: In this cohort of 116,201 new users of AD drugs the proportion of
individuals who had at least one claim for BGMTS was 51%, 58% and 71% among
users of sulfonylureas, metformin and insulin, respectively. The mean weekly
number of strips used was 3.5, 3.7 and 14.6 among users of sulfonylureas, met-
formin and insulin, respectively for an associated mean daily cost of $0.45, $0.48
and $1.81. The proportion of individuals on insulin who received14 BGMTS/week
was 48%. CONCLUSIONS: The proportion of individuals on oral AD who obtained
BGMTS seems high considering this practice is not recommended. On the other
hand it is troublesome that almost the quarter of individuals on insulin did not fill
any claim for BGMTS in their first year of treatment. Almost half of individuals on
insulin used more tests than the suggested maximum weekly limit of 14. Results
suggest there is a need to optimize the use of BGMTS.
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OBJECTIVES:Currently, new techniques for the detection of breast cancer are being
developed that cause less patient discomfort than X-ray mammography. These
techniques might increase screening attendance, and therefore increase the health
gains of the population of women in the Netherlands. One of these techniques is
photo acoustic mammography (PAM). However, it is still unknown how important
attributes such as discomfort, risks and health gains are to its implementation in
breast cancer screening. METHODS: The Analytic Hierarchy Process (AHP), a tech-
nique for multi-criteria analysis, was used to estimate patient and health care
professionals’ preferences for three scenarios of PAM. These scenarios differed in
the diagnostic performance that could be achieved by PAM. Preferences for the
scenarios of PAM were compared with the preferences for X-ray mammography.
Criteria related to the efficiency in applying the technique, diagnostic performance,
patient comfort and safety. We elicited preferences of around 30 health care pro-
fessionals and 300 patients. RESULTS: Health care professionals considered the
sensitivity of the imaging technique to be the criterion of utmost importance in the
selection of a new imaging technique to detect breast cancer. Advantages of less
discomfort have relatively less meaning according to the laboratory workers and
radiologists involved. However, preferences among patients and health care pro-
viders differed. CONCLUSIONS: New techniques to detect breast cancer in screen-
ing programs should at least equal the diagnostic performance of X-ray mammog-
raphy. Additional advantages could slightly increase screening attendance. X-ray
mammography has a relatively lower diagnostic performance for patients with
dense breasts. This subpopulation of patients could be the most promising area for
new detection techniques with a working principle that differs from X-ray mam-
mography.
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OBJECTIVES: Treatment of growth hormone deficiency involves daily subcutane-
ous injections of recombinant human growth hormone (rhGH) and takes place over
many years, incurring substantial costs. Current administration devices exhibit
rhGH wastage during everyday use. We therefore sought to assess the extent of
product wastage with four rhGH administration devices. METHODS: Norditropin®
FlexPro®, NordiFlex® and NovoPen®/SimpleXx® 5mg pens (Novo Nordisk A/S, Bags-
værd, Denmark) and durable Omnitrope®Pen-5 devices (Sandoz, Holzkirchen, Ger-
many) were tested (n40 for each device type in each test). Total rhGH content and
product wastage (rhGH lost before and after injection) were measured in GxP-
compliant laboratory simulations of: time with the needle attached prior to injec-
tion, dose setting, and correcting a set dose. The mass of wasted rhGH from each
pen was measured using an analytical balance and averaged over all devices. Sta-
tistical significance (p0.05) was confirmed using a Student’s t-test and a mathe-
matical model was constructed to estimate annual wastage. RESULTS: The mean
rhGH mass wasted with the needle on prior to injection was 0.0g with all Nordit-
ropin® pens, relative to 94g with Omnitrope® devices. During dose dialing, 0.2–
2.3g of rhGH was lost with Norditropin® pens versus 0.8g with Omnitrope® and
during dose correction, 0.1–0.8g of rhGH was wasted with Norditropin® pens
versus 1.4g with Omnitrope®. Mean total rhGH content was 5.09–5.19mg with
Norditropin® compared to 5.06mg with Omnitrope®. All results were statistically
significant. Annual wastage with Omnitrope® was projected to be 42.4mg per pa-
tient, compared to 5.5–8.3mg with Norditropin®. CONCLUSIONS: Overall, Nordit-
ropin® pens resulted in significantly less wastage when compared with Omni-
trope®. Norditropin® pens were also found to contain significantly more rhGH than
Omnitrope® devices. The study suggests that, in rhGH administration devices of
the same nominal volume, differences exist that materially affect the frequency
with which patients must refill their rhGH prescriptions.
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OBJECTIVES: In Italy, information about clinical outcomes and economic implica-
tions of the treatment with implantable cardioverter defibrillator (ICD) are lacking.
We evaluated time trend in ICD therapy from 2000 to 2008 in Lombardy, an Italian
region with universal health care coverage for more than 9 million people. Subse-
quently, we analysed survival and direct costs following a first implant.METHODS:
We extracted data from DENALI, a data warehouse that organizes health care
administrative data concerning subjects covered by Lombardy Health System(HS).
We estimated annual rates of first implant and of replacement from 2000 to 2008.
We computed the substitution rate using the real person-time at risk, assessed on
subjects with ICD. The cohort of patients who underwent a first ICD implantation
between 2005 and 2007 was followed from discharge to December 31, 2008 in order
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